bell
The current prices are delayed by 15 mins, login to check live prices.
Glaxosmithkline Pharmaceuticals Ltd share price logo

Glaxosmithkline Pharmaceuticals Ltd

(GLAXO)

₹2698.353.33%

as on 04:01PM, 19 Sep 2024

Overview
News
Financials
Q1 2024 Results
Technicals

Analyst Rating

based on 4 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 4 analysts offering long term price targets for Glaxosmithkline Pharmaceuticals Ltd. An average target of ₹2908.75

Source: S&P Global Market Intelligence

Glaxosmithkline Pharmaceuticals Ltd Share analysis

Glaxosmithkline Pharmaceuticals Ltd price forecast by 4 analysts

Upside of4.21%

High

₹3250

Target

₹2908.75

Low

₹2620

Glaxosmithkline Pharmaceuticals Ltd target price ₹2908.75, a slight upside of 4.21% compared to current price of ₹2698.35. According to 4 analysts rating.

Source: S&P Global Market Intelligence

Performance

  • Day's Low

    Day's High

    ₹2,676.25
    ₹2,799.95
  • 52 Week's Low

    52 Week's High

    ₹1,385.05
    ₹3,088
1 Month Return-4.78 %
3 Month Return+ 8.88 %
1 Year Return+ 77.92 %
Previous Close₹2,791.30
Open₹2,791.30
Volume76.78K
Upper Circuit-
Lower Circuit-
Market Cap₹47,286.31Cr

Key Statistics

P/E Ratio62.22
PEG Ratio6.71
Market Cap₹47,286.31 Cr
P/B Ratio18.45
EPS34.83
Dividend Yield1.65
SectorPharmaceuticals
ROE36.83

Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹47,286.31 Cr20%0.56₹589 Cr₹3,453 Cr
BUY₹16,459.31 Cr5.22%0.52₹602 Cr₹2,851 Cr
BUY₹90,184.74 Cr30.78%0.56₹3,168 Cr₹29,001 Cr
HOLD₹1,08,668.24 Cr70.73%0.64₹3,854 Cr₹19,547 Cr
BUY₹59,038.98 Cr36.49%0.53NANA

Company Information

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UKbased GSK Plc. a global biopharma company to unite science technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices a manufacturing facility at Nashik in Maharashtra 22 contract manufacturing organisations CMOs with regional and sales hubs across India. The Company is engaged interalia in the business of manufacturing distributing and trading in pharmaceuticals.The Companys portfolio includes General Medicines Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas such as AntiInfectives Dermatology Gynaecology Diabetes Oncology Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines for the prevention of Hepatitis A Hepatitis B Invasive Disease caused by H Influenza Chickenpox Diphtheria Pertussis Tetanus Rotavirus Cervical Cancer and Others. They have two manufacturing units in India located at Nashik and Thane. Also they have a clinical development centre in Bangalore. GlaxoSmithKline Pharma Limited was incorporated in November 13 1924. During year 1956 the Company began primary production of vaccines at Worli. In the year 1960 the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961 the Company started manufacturing Vitamin A and Betamethasone at new plant at Thane using imported raw materials. The Company registered as a limited company in the year 1968. Also they introduced the Animal health products. In the year 1971 the company built the Research development laboratory at Thane. Also they relocated the SmithKline French plant from Mumbai to Bangalore. In the year 1983 they commissioned the Nashik factory. SmithKline Beecham became a public limited company under the new name of Eskayef Ltd in the year 1984 and one new Plant was set up in Mysore for manufacture of bulk drugs. In the year 1985 the companys second basic drugs factory was inaugurated at Ankleshwar Gujarat. In the year 1986 the company launched joint venture projects Vegepro Foods and Feeds Ltd and K G Gluco Biols. The companys name was changed to Glindia Ltd in the year 1987. In the year 1988 the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also they started a joint venture project with Hindustan Foods Ltd for the manufacture of extruded foods at Usgao Goa. In the year 1989 the company commenced their Zinetac production at Nashik. The companys name was changed from Glindia Ltd to Glaxo India Ltd. In the year 1990 the production of the bulk drug cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. Glaxo rated amongst the first five of Indias most respected companies 4th place in a survey by Businessworld magazine. An agreement was signed with the Council of Scientific and Industrial Research CSIR during 1991. In the year 1992 the company sold their trade investments in Vegepro and Feeds Ltd. In the year 1993 they sold their investment in Hindustan Foods Ltd and Dempo Dairy Industries Ltd. Cetzine a secondgeneration antihistamine and research product of UCB Pharma Belgium was launched under a comarketing agreement. In the same year Glaxo received recognition from the Ministry of Commerce as an export house. In the year 1994 the company sold their Family Products Division to H J Heinz for a sum of Rs 210 crore. The Mysore plant received ISO 9002 certification and the new Iodex plant was inaugurated in Bangalore. In the year 1995 they inaugurated the government approved stateoftheart Pharmacy Research Development Centre PRD at Thane to cater to the unmet medical needs and to exploit local commercial opportunities.In the year 1998 the company acquired Biddle Sawyer Group of Companies which was struggled in the year before. In the year 2000 Agrivet Farm Care AFC tied up with Merial the worlds largest Animal Health Company to market poultry vaccines. The company ranked 6th in Business Today Stern Stewart Co. listing of Indias best Wealth Creator Companies and also the launched Seretide for Asthma. The merger of SmithKline Beecham Pharmaceuticals India Ltd into Glaxo India Limited was completed and the name of the company was changed to the present name GlaxoSmithKline Pharmaceuticals Ltd. Businessworld and the Indian Market Research Bureau IMRB named GlaxoSmithKline as Indias most respected Pharmaceutical Company in a survey in the year 2003. During the year the company launched Cetzine Cetirizine antihistamine Zimig terbinafine antiinfective CCM calcium citrate maleate nutritional Cobadex CZS multivitamin with trace elements.In the year 2004 the company launched Priorix measles mumps rubella vaccine. In the year 2005 the company launched oral contraceptives: Elogen desogestrel and ethinylestradiol and Zerogen progesterone only pill. They entered into the diabetes therapeutic segment with the launch of Windia rosiglitazone and Windamet rosiglitazone and metformin. In the year 2006 the company made an inlicensing alliance with Eisai Pharmaceuticals Japan and launched Parit rabeprazole gastrointestinal therapy area. Also GlaxoSmithKline divested their Agrivet Farm Care AFC animal health business. In the year 2007 the company launched Carzec carvedilol and Zemetril cefprozil.

Share Price: ₹2698.35 per share as on 19 Sep, 2024 04:01 PM
Market Capitalisation: ₹47,286.31Cr as of today
Revenue: ₹814.65Cr as on June 2024 (Q2 24)
Net Profit: ₹182.33Cr as on June 2024 (Q2 24)
Listing date: 03 Nov, 1994
Chairperson Name: Renu S Karnad
OrganisationGlaxosmithkline Pharmaceuticals Ltd
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Glaxosmithkline Pharmaceuticals Ltd

  • GSK Pharmaceuticals Faces GST Demand Order - 16 Sep, 2024

    GlaxoSmithKline Pharmaceuticals Limited received a GST demand order of ₹1.07 crore from the Telangana Commissioner for discrepancies in GST returns from FY 2017-18 to 2021-22. The company plans to appeal the order.

  • GSK Pharma Secures Significant Tax Refund Order - 04 Sep, 2024

    Glaxosmithkline Pharmaceuticals has received an order from the Income Tax Department for a refund of Rs 222.23 crore for the Assessment Year 2022-23, enhancing its financial position.

  • GlaxoSmithKline Pharma Reports Tax Refund and Strong Q1 Growth - 03 Sep, 2024

    GlaxoSmithKline Pharmaceuticals received a ₹222.23 crore income tax refund for FY 2022-23. The company reported a 37.8% YoY increase in Q1 net profit to ₹182.3 crore, with revenue rising 7% to ₹814.7 crore. Key brands and the respiratory portfolio showed significant growth, contributing to a strong EBITDA margin of 28.3%. Shares rose by 1.94% to ₹2,836.20.

  • GSK Pharma Sees Strong Gains Post Q1 Results - 21 Aug, 2024

    GlaxoSmithKline Pharmaceuticals' stock rose 5.7% to Rs 3,059, marking an 11% increase since its recent results. The stock has gained 57% since April, outperforming the BSE Healthcare index and Sensex, driven by better-than-expected Q1 performance with a 7% uptick.

Insights on Glaxosmithkline Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 3.48% to 4.02% in Jun 2024 quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 4.51% to 4.71% in Jun 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 142.7% return, outperforming this stock by 58.3%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 75.00% of holdings in Jun 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Torrent Pharmaceuticals Ltd has given 78.3% return, outperforming this stock by 0.4%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, GLAXO stock has moved down by -2.5%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 13.62% to 13.48% in Jun 2024 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 962.03 Cr → 850.29 Cr (in ₹), with an average decrease of 11.6% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 194.48 Cr → 182.33 Cr (in ₹), with an average decrease of 6.3% per quarter

Company Financials

Value in ₹ crore
DetailsQ'2 23Q'3 23Q'4 23Q'1 24Q'2 24
Revenue₹761.66Cr (-)₹956.99Cr (↑25.65%)₹805.26Cr (↓15.85%)₹929.80Cr (↑15.47%)₹814.65Cr (↓12.38%)
Net Income₹132.25Cr (-)₹217.51Cr (↑64.47%)₹45.72Cr (↓78.98%)₹194.48Cr (↑325.37%)₹182.33Cr (↓6.25%)
Net Profit Margin17.36% (-)22.73% (↑30.93%)5.68% (↓75.01%)20.92% (↑268.31%)22.38% (↑6.98%)
Value in ₹ crore
Details2021202220232024
Total Assets₹3,112.65Cr (-)₹4,641.49Cr (↑49.12%)₹3,345.90Cr (↓27.91%)₹3,564.93Cr (↑6.55%)
Total Liabilities₹1,615.53Cr (-)₹1,963.87Cr (↑21.56%)₹1,592.90Cr (↓18.89%)₹1,780.83Cr (↑11.80%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹490.97Cr (-)₹594.87Cr (↑21.16%)₹819.79Cr (↑37.81%)₹487.94Cr (↓40.48%)₹578.94Cr (↑18.65%)

Index Inclusions

S&P BSE 150 MidCap

₹16,794.37

-0.4 (-67.06%)

BSE 200

₹11,726.75

-0.04 (-4.26%)

Nifty 500

₹23,853.95

-0.19 (-44.7%)

S&P BSE Quality

₹2,034.26

-0.98 (-20.16%)

Nifty Midcap 150

₹21,965.15

-0.52 (-114.75%)

BSE Healthcare

₹43,655.30

-0.25 (-108.18%)

BSE Mid-Cap

₹48,600.14

-0.53 (-256.93%)

S&P BSE 400 MidSmallCap

₹12,769.65

-0.61 (-78.92%)

S&P BSE 250 LargeMidCap

₹11,128.91

-0.04 (-4.49%)

Nifty MidSmallcap 400

₹20,684.65

-0.73 (-152.4%)

Nifty LargeMidcap 250

₹16,631.60

-0.25 (-41.65%)

S&P BSE Momentum

₹2,390.30

-0.97 (-23.31%)

BSE 500

₹37,616.67

-0.14 (-51.62%)

S&P BSE AllCap

₹11,001.59

-0.22 (-24.68%)

Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
75%
0.00
Foreign Institutions
4.02%
15.51
Mutual Funds
4.71%
4.38
Retail Investors
13.48%
-1.05
Others
2.8%
-17.50

Key Indicators

Details20202021202220232024
Return On Equity %9.928.4980.4527.4336.83
Details20202021202220232024
Return On Assets %2.9611.5136.5118.2516.55
Details20202021202220232024
Book Value Per Share (₹)107.4787.26157.19102.79104.93
Details20202021202220232024
Earning Per Share (₹)5.521.14100.0436.0534.83

Glaxosmithkline Pharmaceuticals Ltd Valuation

Glaxosmithkline Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (-81.64x)

December 28, 2020

Industry (58.50x)

September 18, 2024

Today (62.22x)

September 18, 2024

Highest (333.07x)

September 15, 2020

LowHigh

Earnings and Dividends

  • Glaxosmithkline Pharmaceuticals Ltd Earnings Results

    Glaxosmithkline Pharmaceuticals Ltd’s net profit jumped 37.87% since last year same period to ₹182.33Cr in the Q1 2024-2025. On a quarterly growth basis, Glaxosmithkline Pharmaceuticals Ltd has generated -6.25% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Glaxosmithkline Pharmaceuticals Ltd Dividends May,2024

    In the quarter ending March 2024, Glaxosmithkline Pharmaceuticals Ltd has declared dividend of ₹32 - translating a dividend yield of 2.29%.

    Read More about Dividends

Technicals Summary

Bearish

Neutral

Bullish

Bearish

Glaxosmithkline Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Glaxosmithkline Pharmaceuticals Ltd shares.

Glaxosmithkline Pharmaceuticals Ltd (GLAXO) share price today is ₹2698.35

Glaxosmithkline Pharmaceuticals Ltd is listed on NSE

Glaxosmithkline Pharmaceuticals Ltd is listed on BSE

  • Today’s highest price of Glaxosmithkline Pharmaceuticals Ltd is ₹2799.95.
  • Today’s lowest price of Glaxosmithkline Pharmaceuticals Ltd is ₹2676.25.

PE Ratio of Glaxosmithkline Pharmaceuticals Ltd is 62.22

PE ratio = Glaxosmithkline Pharmaceuticals Ltd Market price per share / Glaxosmithkline Pharmaceuticals Ltd Earnings per share

Today’s traded volume of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is 76.78K.

Today’s market capitalisation of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is ₹47286.31Cr.

Glaxosmithkline Pharmaceuticals Ltd(GLAXOPrice
52 Week High
₹3088
52 Week Low
₹1385.05

Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2698.35. It is down -12.62% from its 52 Week High price of ₹3088

Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2698.35. It is up 94.82% from its 52 Week Low price of ₹1385.05

Glaxosmithkline Pharmaceuticals Ltd(GLAXOReturns
1 Day Returns
-92.95%
1 Month Returns
-4.78%
3 Month Returns
8.88%
1 Year Returns
77.92%